{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-002796","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.785998+00:00","generated_at":"2026-05-15T02:35:46.535500+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash","bullets":["Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).","Key innovative brands: AUSTEDO $578M (+41% YoY), AJOVY $196M (+35%), UZEDY $63M (+62%).","Generics down 16% LC due to lenalidomide competition and Japan BV divestiture.","Acquired Emalex Biosciences for $700M upfront + up to $200M milestones + royalties; ecopipam (Tourette) NDA-ready; close expected Q3 2026.","2026 outlook maintained; Non-GAAP diluted EPS $1.91-$2.11 (stand-alone $2.57-$2.77)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002796","json":"https://secwatch.observer/filing/0001171843-26-002796.json","markdown":"https://secwatch.observer/filing/0001171843-26-002796.md","text":"https://secwatch.observer/filing/0001171843-26-002796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/0001171843-26-002796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/f8k_042926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:35:46.535500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4257cf3545311cbec4f0cd0dccc27aff1ea68506","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported quarter ended March 31, 2026 results: revenue Revenues of $4.0 billion, EPS GAAP diluted EPS of $0.31. Guidance reaffirmed.","evidence_excerpt":"Q1 2026 Highlights: Revenues of $4.0 billion GAAP diluted EPS of $0.31 Non-GAAP diluted EPS of $0.53 Cash flow used in operating activities of $40 million Free cash flow of $188 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/0001171843-26-002796-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Revenue","value":"Revenues of $4.0 billion"},{"label":"EPS","value":"GAAP diluted EPS of $0.31"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}